CollPlant Biotechnologies (CLGN) EBIT Margin (2017 - 2026)
CollPlant Biotechnologies' (CLGN) quarterly EBIT Margin came in at 4267.12% in Q1 2026, down 418693.0% on a YoY basis from N/an in Q1 2025, and up 18.72% quarter-over-quarter from 5250.0% in Q4 2025.
Powered by 
Analysis
CollPlant Biotechnologies (CLGN) EBIT Margin (2017 - 2026) Analysis & Trends
CollPlant Biotechnologies (CLGN) has reported EBIT Margin for 10 consecutive years, with 4267.12% the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, EBIT Margin fell 418693.0% year-over-year to 4267.12%; the trailing twelve-month figure through Mar 2026 stood at 1695.12% (down 146219.0% YoY), and the FY2025 full-year result was 484.31%, up 286540.0% from the prior year.
- EBIT Margin improved to 4267.12% in Q1 2026 per CLGN's latest filing, from 5250.0% in the prior quarter.
- Across five years, EBIT Margin topped out at 4417.35% in Q1 2024 and bottomed at 113550.0% in Q3 2024.
- Historically, EBIT Margin has averaged 9512.11% across 5 years, with a median of 3261.13% in 2022.
- The sharpest annual moves came in 2024 and 2025: EBIT Margin sank 10284767 bps in 2024, then surged 10899545 bps in 2025.
- Over 5 years, EBIT Margin stood at 8062.07% in 2022, then jumped by 79 bps to 1694.98% in 2023, then plunged by 43 bps to 2423.17% in 2024, then slumped by 117 bps to 5250.0% in 2025, then rose by 19 bps to 4267.12% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 4267.12%, 5250.0%, and 4554.55% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -25,380.93% |
| 10 | CollPlant Biotechnologies | 4.17 Mn | 4.17 Mn | -243,000.00 | -4,267.12% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 30, 2026 | -4,267.12% |
| Dec 31, 2025 | -5,250.00% |
| Sep 30, 2025 | -4,554.55% |
| Jun 30, 2025 | 1,775.42% |
| Mar 30, 2025 | -80.19% |
| Dec 31, 2024 | -2,423.17% |
| Sep 30, 2024 | -113,550.00% |
| Jun 30, 2024 | 1,769.48% |
| Mar 31, 2024 | 4,417.35% |
| Dec 31, 2023 | -1,694.98% |
| Sep 30, 2023 | -10,702.33% |
| Jun 30, 2023 | 55.74% |
| Mar 31, 2023 | 812.70% |
| Dec 31, 2022 | -8,062.07% |
| Sep 30, 2022 | -4,099.08% |
| Jun 30, 2022 | -6,340.91% |
| Dec 31, 2021 | -1,227.10% |
| Sep 30, 2021 | -2,210.00% |
| Jun 30, 2021 | -443.27% |
| Mar 31, 2021 | 69.14% |